ProKidney (MEX:PROK) Debt-to-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Debt-to-Asset?

ProKidney's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was MXN18.91 Mil. ProKidney's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was MXN103.33 Mil. ProKidney's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was MXN9,144.72 Mil. ProKidney's debt to asset for the quarter that ended in Jun. 2024 was 0.01.

ProKidney Debt-to-Asset Historical Data

The historical data trend for ProKidney's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Debt-to-Asset Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.09

0.03

0.01

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial										0.01	0.01	0.01	0.02	0.01

Competitive Comparison of ProKidney's Debt-to-Asset

For the Biotechnology subindustry, ProKidney's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProKidney's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ProKidney's Debt-to-Asset falls into.

ProKidney Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ProKidney's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13.63	+	61.277)	/	7138.554
	=	0.01

ProKidney's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(18.906	+	103.325)	/	9144.718
	=	0.01

ProKidney (MEX:PROK) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ProKidney Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ProKidney's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.